Figure 1.
Schematic of study design, patient disposition, and thrombocytopenia as a function of schedule dose. (A) Screening and enrollment data for all patients. (B-D) Platelet trend over time. Platelet-retreatment parameter is 50 000/μL. (B) Cohort 1 patients were treated with pralatrexate 10 mg/m2 and romidepsin 12 mg/m2 on days 1, 8, and 15 every 28 days. (C) Cohorts treated on schedule A received pralatrexate 15 to 20 mg/m2 and romidepsin 12 to 14 mg/m2 on days 1 and 8 every 21 days. (D) Cohorts treated on schedule B received pralatrexate 15 to 25 mg/m2 and romidepsin 12 to 14 mg/m2 days 1 and 15 every 28 days. C, cycle; D, day; SCR, screening.
